Skip to main content
Signal8
Launch Terminal

ADMA BIOLOGICS, INC. (ADMA)

ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

ADMA Biologics, Inc. logo

ADMA Biologics, Inc.

NASDAQ:ADMAHealthcare
-2.89%$11.41
AH$11.25-1.40%vs close
Mkt Cap$2.56B
Float215.07M
O/S223.98M
Vol
$ Vol
RVOL
Inst Own90.5%
SI9.1%
Earnings
Dilution
ADMA Biologics, Inc. logoNASDAQ:ADMA$11.41-2.89%
Phase Distribution
7 lead-sponsored trials·0 active·4 completed
Phase 22
Phase 32
Phase 42
Not applicable1
Status Overview
Completed4
Stopped1
Unknown2

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 4
    Completed

    Study to Evaluate Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Subjects Aged 2 to 16

    Bivigam

    Humoral Immune Response

    Enrollment
    16
    Start
    Dec 2016
    Primary Completion
    Aug 2022
    Completion
    Dec 2022
    NCT03164967
  • Phase 4
    Unknown status

    An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD)

    Asceniv™

    Primary Immune Deficiency

    Enrollment
    12
    Start
    Sep 2022
    Primary Completion
    Mar 2023est.
    Completion
    Jun 2023est.
    NCT05070455
  • Phase 3
    Completed

    Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)

    Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]

    Primary Immune Deficiency Disorders (PIDD)

    Enrollment
    63
    Start
    Sep 2007
    Primary Completion
    Jul 2009
    Completion
    Jul 2009
    NCT00538915
  • Phase 3
    Completed

    Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)

    RI-002

    Primary Immune Deficiency Disorder

    Enrollment
    59
    Start
    Feb 2014
    Primary Completion
    Dec 2014
    Completion
    Jan 2015
    NCT01814800
  • Phase 2
    Terminated

    Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation

    Hepatitis C Immune Globulin Intravenous (Human) 5%

    Sequelae of Viral Hepatitis, Transplantation Infection +1

    Enrollment
    7
    Start
    May 2007
    Primary Completion
    Feb 2009
    Completion
    Feb 2009
    NCT00473824
  • Phase 2
    Completed

    RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness

    RI-001, RI-001

    Upper Respiratory Tract Infection, Lower Respiratory Tract Infection

    Enrollment
    21
    Start
    Feb 2008
    Primary Completion
    May 2010
    Completion
    May 2010
    NCT00632463
  • Observational
    Unknown status

    A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Disease Treated With Immune Globulin Products

    Bivigam, Other

    Primary Immune Deficiency Disorder

    Enrollment
    200
    Start
    Dec 2016
    Primary Completion
    Dec 2022
    Completion
    Jun 2023est.
    NCT03037359
Search ClinicalTrials.gov for “Adma Biologics”